深度解析医学证据，DeepEvidence为你支撑决策

2026年5月24-27日，第94届欧洲动脉粥样硬化学会年会（EAS 2026）将在希腊雅典盛大举办。作为血脂领域的年度风向标，本届大会发布了关于PCSK9抑制剂的突破性数据。从口服PCSK9抑制剂Enlicitide的III期临床药理学数据，到Lerodalcibep在纯合子家族性高胆固醇血症（HoFH）中的长期安全性与有效性，再到碱基编辑（VERVE-102）及表观遗传沉默（STX-1150）等下一代基因治疗策略，大会集中展示了PCSK9靶点从单抗、口服小分子到体内基因编辑的全方位迭代，为极高危心血管患者的血脂管理带来了全新希望。POCKETIN特别梳理EAS 2026大会的PCSK9抑制剂领域重点日程，带您抢先聚焦最新突破与未来方向。

05月25日

New perspectives on lipid lowering therapies
北京时间：16:50
THE LONG-TERM EFFICACY AND SAFETY OF LERODALCIBEP IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA
LERODALCIBEP在纯合子家族性高胆固醇血症中的长期有效性和安全性

David Kallend (United States of America)

SaaG Session: Cellular LDL Handling and Intracellular Lipid Metabolism
北京时间：18:37
REGULATION OF LIPOLYSIS AND LIPOGENESIS BY STAT1 AND STAT3 IN CONDITIONS OF ANGPTL3 AND PCSK9 EXPRESSION MODULATION - A CHIPSEQ ANALYSIS
STAT1和STAT3在ANGPTL3和PCSK9表达调节条件下对脂解和脂生成的调控——一项CHIPSEQ分析

Simone Bini (Italy)

SaaG Session: Systemic Lipid and Lipoprotein Metabolism in Cardiovascular Disease
北京时间：19:56
IDENTIFICATION OF SMALL CHEMICAL GRP78 BINDERS THAT MITIGATE PCSK9 EXPRESSION AND SECRETION: POTENTIAL THERAPEUTIC STRATEGY FOR HYPERLIPIDEMIA
鉴定能减轻PCSK9表达和分泌的小分子GRP78结合剂：高脂血症的潜在治疗策略

Madeline Triolo (Canada)

北京时间：20:17
PCSK9 TARGETING THERAPIES DO NOT AFFECT THE BINDING OF PCSK9 TO CIRCULATING LIPOPROTEINS
靶向PCSK9的治疗不影响PCSK9与循环脂蛋白的结合

Riccardo Rizzo (Italy)

SaaG Session: Intensive Lipid-Lowering Strategies in High-Risk Cardiovascular Patients
北京时间：19:05
AN OVERVIEW OF THE CLINICAL PHARMACOLOGY OF ENLICITIDE DECANOATE: A FIRST-IN-CLASS ORAL PCSK9 INHIBITOR
Enlicitide Decanoate的临床药理学概述：一种首创的口服PCSK9抑制剂

Douglas G. Johns (United States of America)

Late Breaker Abstracts in PCSK9 pharmacology
北京时间：20:45
IN VIVO BASE EDITING OF PCSK9 WITH VERVE-102 ENABLES POTENT AND DURABLE LDL-C REDUCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA
使用VERVE-102对PCSK9进行体内碱基编辑，可在高胆固醇血症患者中实现强效且持久的LDL-C降低

Scott B. Vafai (United States of America)

北京时间：21:03
EFFECT OF ENLICITIDE, AN ORAL PCSK9 INHIBITOR, ON APOLIPOPROTEIN-B (APOB) IN PHASE 3 TRIALS
口服PCSK9抑制剂Enlicitide在3期试验中对载脂蛋白B的影响

Alberico L. Catapano (Italy)

北京时间：21:21
EPIGENETIC PCSK9 SILENCING WITH STX-1150 PROVIDES DURABLE LDL-C CONTROL AFTER A SINGLE DOSE
使用STX-1150进行表观遗传PCSK9沉默，单次给药后提供持久的LDL-C控制

Benjamin L. Oakes (United States of America)

北京时间：21:39
LIPOPROTEIN(A) LEVELS, RISK OF CARDIOVASCULAR EVENTS AND BENEFIT OF EVOLOCUMAB: FINDINGS FROM THE VESALIUS-CV TRIAL.
脂蛋白(a)水平、心血管事件风险以及依洛尤单抗的获益：来自VESALIUS-CV试验的研究结果

Victorien Monguillon (United States of America)

北京时间：21:57
EFFICACY AND SAFETY OF LERODALCIBEP, A NOVEL THIRD GENERATION PCSK9 INHIBITOR, IN SUBJECTS WITH SEVERE LDL-C ELEVATIONS COMPLETING THE 124-WEEK OPEN-LABEL PHASE 3 EXTENSION STUDY
新型第三代PCSK9抑制剂Lerodalcibep在完成124周开放标签3期扩展研究的重度LDL-C升高受试者中的有效性与安全性

David Kallend (United States of America)

05月27日

Plenary 03: New Frontiers in ASCVD Management
北京时间：14:36
The PCSK Family in CVD and Beyond
CVD及其他领域中的PCSK家族

Nabil G. Seidah (Canada)

05月26日

SaaG Session: Clinical Management and Therapeutic Optimization in Familial Hypercholesterolemia
北京时间：19:49
EFFECTS OF PCSK9 MONOCLONAL ANTIBODIES ON ATHEROTHROMBOTIC PATHWAYS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
PCSK9单克隆抗体对家族性高胆固醇血症患者动脉粥样硬化血栓形成通路的影响

Aikaterini N. Tsouka (Greece)

SaaG Session: Genetic Determinants of Inherited Dyslipidemias
北京时间：18:51
DEVELOPMENT OF AN INTERACTIVE DATABASE OF LDLR, APOB, PCSK9, AND LDLRAP1 VARIANTS AND GENOTYPES OBSERVED IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
开发一个交互式数据库，收录在纯合子家族性高胆固醇血症中观察到的LDLR、APOB、PCSK9和LDLRAP1变异及基因型

Mafalda Bourbon (Portugal)

SaaG Session: Hepatic and Adipose Tissue Metabolism and Crosstalk in Cardiometabolic Disease
北京时间：20:10
HEPATIC IP3R1 DELETION MITIGATES PCSK9 EXPRESSION/SECRETION TO LOWER CIRCULATING PCSK9 AND LDL CHOLESTEROL LEVELS IN MICE
肝脏IP3R1缺失可减轻PCSK9的表达/分泌，从而降低小鼠循环中的PCSK9和LDL-C水平

Derek W. Stouth (Canada)

SaaG Session: Genomic and Epigenomic Architecture of Cardiometabolic Disease
北京时间：20:03
IMPACT OF 3'-UTR MIRNA-RELATED SNPS IN LDLR AND PCSK9 GENES AS MODIFIERS OF THE HYPERCHOLESTEROLEMIC PHENOTYPE IN FAMILIAL HYPERCHOLESTEROLEMIA
LDLR和PCSK9基因中3'-UTR miRNA相关SNP作为家族性高胆固醇血症高胆固醇表型修饰因子的影响

Ana M. Medeiros (Portugal)